Pancreatic Cancer Research

ResearcherCenter of Medical Innovation and Translational Research, The University of OsakaActive in the last 2 years

Kazuki Sasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-9126-0351; OpenAlex author ID A5109577574. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2022: 5 papers · 2023: 6 papers · 2024: 11 papers · 2025: 6 papers · 2026: 2 papers

Papers 30

  1. Chondroitinase ABC enhances trastuzumab activity via cell-surface chondroitin sulfate cleavage in pancreatic cancer cells. First author DOI 10.1016/j.bbrc.2026.153774↗
  2. Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Co-author DOI 10.1038/s41598-026-48779-7↗
  3. Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradio… Co-author DOI 10.1016/j.pan.2025.06.016↗
  4. Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases. Co-author DOI 10.1016/j.suronc.2025.102225↗
  5. miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential… Co-author DOI 10.1245/s10434-024-16115-w↗
  6. ASO Author Reflections: Potential of Peripheral Plasma Exosomal miRNA: miR-6855-5p Could Predict Radiosensitivity in Patients with Pancreatic Cancer, and Enhan… Co-author DOI 10.1245/s10434-024-16235-3↗
  7. Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17482-8↗
  8. ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17667-1↗
  9. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.34725↗
  10. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  11. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… Co-author DOI 10.1016/j.ejso.2024.108650↗
  12. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network anal… Co-author DOI 10.1016/j.pan.2024.09.009↗
  13. Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological h… Co-author DOI 10.1016/j.suronc.2024.102103↗
  14. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Co-author DOI 10.1111/cas.16152↗
  15. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… Co-author DOI 10.1245/s10434-024-15021-5↗
  16. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15118-x↗
  17. ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15349-y↗
  18. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0310328↗
  19. Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality. Co-author DOI 10.3892/ijo.2024.5662↗
  20. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  21. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. Co-author DOI 10.1007/s00423-023-03089-8↗
  22. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  23. Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: Current understanding and future directions. Co-author DOI 10.1111/cas.15890↗
  24. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… Co-author DOI 10.1245/s10434-022-12985-0↗
  25. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… Co-author DOI 10.1245/s10434-022-13024-8↗
  26. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
  27. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  28. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  29. Emerging roles of long noncoding and circular RNAs in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fphys.2022.1025923↗
  30. Pancreatic Cancer Research beyond DNA Mutations. First author DOI 10.3390/biom12101503↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 29 shared papers, 2022–2026 · strength 5.23
  2. Daisaku Yamada · 26 shared papers, 2022–2026 · strength 4.79
  3. Yoshito Tomimaru · 25 shared papers, 2022–2026 · strength 4.63
  4. Yoshifumi Iwagami · 23 shared papers, 2022–2026 · strength 4.27
  5. Hidetoshi Eguchi · 23 shared papers, 2022–2025 · strength 3.86
  6. Tadafumi Asaoka · 20 shared papers, 2022–2026 · strength 3.72
  7. Hidenori Takahashi · 18 shared papers, 2022–2025 · strength 3.10
  8. Hirofumi Akita · 10 shared papers, 2022–2026 · strength 1.84
  9. Masahiro Tanemura · 8 shared papers, 2022–2024 · strength 1.27
  10. Hidetoshi Eguchi · 5 shared papers, 2025 · strength 1.13
  11. Hiroki Ueda · 5 shared papers, 2023–2025 · strength 0.96
  12. Hideshi Ishii · 6 shared papers, 2022–2024 · strength 0.88
  13. Satoru Miyahara · 4 shared papers, 2024–2026 · strength 0.87
  14. Shinichiro Hasegawa · 4 shared papers, 2024–2026 · strength 0.81
  15. Masahiko Kubo · 4 shared papers, 2024–2025 · strength 0.79
  16. Tomoaki Hara · 5 shared papers, 2022–2024 · strength 0.77
  17. Hiromichi Sato · 5 shared papers, 2022–2024 · strength 0.77
  18. Kunihito Gotoh · 5 shared papers, 2022–2024 · strength 0.75
  19. Yu Takeda · 4 shared papers, 2022–2024 · strength 0.66
  20. Masao Nakamura · 1 shared paper, 2026 · strength 0.63
  21. Yoshiko Tsuji · 4 shared papers, 2022–2024 · strength 0.62
  22. Sikun Meng · 3 shared papers, 2023–2024 · strength 0.49
  23. Ryosuke Maki · 2 shared papers, 2025 · strength 0.44
  24. Kazuhiko Ogawa · 3 shared papers, 2022–2024 · strength 0.42
  25. Shotaro Tatekawa · 3 shared papers, 2022–2024 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.